Positive Support Services in North Yorkshire and York
NYAA provides support for people in North Yorkshire and York who are living with or affected by HIV. From 1st July 2015, our support services will be delivered as part of our Partnership with York Teaching Hospital NHS under the recognised name YorSexualHealth.
On this website, you can find more information about who we are in the “About NYAA” section and what we do – what services we can provide – in the “Services” section. There is also an overview of information about HIV and HIV treatment in the “Information About HIV” section, with suggestions on where to find reliable, more detailed information. And there is also a “News” section, for news not only about NYAA, but also about things to do with HIV that might be of interest.
You can find our contact details here.
Topics on this page include the following: you can jump to them by clicking on the headings below:
Co-infection with HCV increases cancer risk for people with HIV
As a result of highly-active antiretroviral therapy (HAART), many people with HIV now have a near-normal life expectancy. However, rates of serious non-HIV-related illnesses are higher among people with HIV compared to individuals in the general population. Several studies have shown that even for people taking effective HAART, they have higher risk of several malignancies not traditionally associated with HIV infection.
In high-income countries such as the UK, approximately a third of people with HIV also have hepatitis C (HCV) co-infection. This infection on its own has been associated with an increase in liver cancer and also with certain other malignancies, including lymphoma. Little is known about the impact of HCV co-infection on cancer risk for people with HIV.
A new study has found that HIV/HCVco-infected patients presented more NADC [non-AIDS-defining cancer] than HIV-mono-infected. The authors of the study say “Treatment of HCV infection and HIV virological control are fundamental strategies but the valuable role of cancer-screening programs and early treatment must be assessed.”
Full details can be found here.
Nurse-led intervention improves adherence to ART and is cost-effective
Thanks to HAART (highly active anti-retroviral therapy), many people living with HIV now have a near-normal life expectancy. Modern anti-HIV drugs are very effective, have mild or no side-effects and are usually one or two pills taken once daily. However, for HAART to remain effective, it is critical that the HIV drugs are taken on time, every time – this is called adherence. This can be difficult for some people, and so thought has been given to how best to support people struggling with adherence.
To date, no high-quality study has provided strong evidence of the effectiveness and cost-effectiveness of adherence support strategies (though there is plenty of anecdotal evidence that a range of support strategies can be beneficial). A new, high-quality study has looked at a nurse-led intervention strategy called AIMS for improving adherence. It was able to show clear benenfits in terms of adhenece, and therefore, preventing virological failure. “AIMS requires few resources, is feasible to deliver in routine care, and is acceptable to health-care providers and patients,” write the authors. “The AIMS intervention should be scalable and the results generalisable to the wider population of patients and HIV clinics – at least in high-income settings. Implementation of AIMS in routine HIV clinical care is therefore strongly recommended.”
Full details of the study can be found here.